Rebecca Taub - 11 Aug 2025 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Director
Signature
/s/ Mardi Dier, as Attorney-in-Fact
Issuer symbol
MDGL
Transactions as of
11 Aug 2025
Net transactions value
-$16,069,956
Form type
4
Filing time
13 Aug 2025, 17:33:26 UTC
Previous filing
22 Jul 2025
Next filing
12 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Taub Rebecca Director C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Mardi Dier, as Attorney-in-Fact 13 Aug 2025 0001423898

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Options Exercise $30,240 +3,200 +0.69% $9.45 464,244 11 Aug 2025 Direct
transaction MDGL Common Stock Sale $1,043,528 -2,980 -0.64% $350.18 461,264 11 Aug 2025 Direct F1, F2
transaction MDGL Common Stock Sale $77,225 -220 -0.05% $351.02 461,044 11 Aug 2025 Direct F1, F3
transaction MDGL Common Stock Options Exercise $408,835 +43,263 +9.4% $9.45 504,307 12 Aug 2025 Direct
transaction MDGL Common Stock Sale $1,256,127 -3,580 -0.71% $350.87 500,727 12 Aug 2025 Direct F1, F4
transaction MDGL Common Stock Sale $1,009,091 -2,870 -0.57% $351.60 497,857 12 Aug 2025 Direct F1, F5
transaction MDGL Common Stock Sale $414,130 -1,175 -0.24% $352.45 496,682 12 Aug 2025 Direct F1, F6
transaction MDGL Common Stock Sale $1,623,997 -4,587 -0.92% $354.04 492,095 12 Aug 2025 Direct F1, F7
transaction MDGL Common Stock Sale $2,299,873 -6,479 -1.3% $354.97 485,616 12 Aug 2025 Direct F1, F8
transaction MDGL Common Stock Sale $2,047,436 -5,752 -1.2% $355.95 479,864 12 Aug 2025 Direct F1, F9
transaction MDGL Common Stock Sale $1,735,861 -4,864 -1% $356.88 475,000 12 Aug 2025 Direct F1, F10
transaction MDGL Common Stock Sale $2,402,982 -6,715 -1.4% $357.85 468,285 12 Aug 2025 Direct F1, F11
transaction MDGL Common Stock Sale $2,346,983 -6,541 -1.4% $358.81 461,744 12 Aug 2025 Direct F1, F12
transaction MDGL Common Stock Sale $251,798 -700 -0.15% $359.71 461,044 12 Aug 2025 Direct F1, F13
holding MDGL Common Stock 655,540 11 Aug 2025 By SQN LLC F14

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -3,200 -6.9% $0.000000 43,263 11 Aug 2025 Common Stock 3,200 $9.45 Direct F15
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -43,263 -100% $0.000000 0 12 Aug 2025 Common Stock 43,263 $9.45 Direct F15
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.00 to $351.24, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.10 to $351.08, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.16 to $352.12, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $352.17 to $353.01, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.43 to $354.42, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.44 to $355.43, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.44 to $356.43, inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.44 to $357.41, inclusive.
F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.44 to $358.43, inclusive.
F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.44 to $359.43, inclusive.
F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.51 to $359.78, inclusive.
F14 The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F15 The shares underlying this stock option are fully vested and exercisable.